Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Taiwan ergonomic pillow OEM factory supplier

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Vietnam ergonomic pillow OEM supplier

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Vietnam high-end foam product OEM/ODM

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Cushion insole OEM manufacturing facility Taiwan

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Custom foam pillow OEM in Indonesia

Older people become more susceptible to cold. Human evolution has provided us a level of protection from the existential threat of cold temperatures with the capacity to produce heat from fat stored in the body. However, with age, people become more susceptible to cold as well as inflammation and metabolic problems which can lead to a host of chronic diseases. Researchers at Yale and the University of California-San Francisco (UCSF) have found one culprit in this process — the same immune cells within fat that are designed to protect us from cold temperatures. In a new study, they find that the fat tissue of older mice loses the immune cell group 2 innate lymphoid cells (ILC2) which restore body heat in the presence of cold temperatures. But in a cautionary tale for those seeking easy treatments for diseases of aging, they also found that stimulating the production of new ILC2 cells in aging mice actually makes them more prone to cold-induced death. “What is good for you when you are young, can become detrimental to you as you age,” said Vishwa Deep Dixit, the Waldemar Von Zedtwitz Professor of Comparative Medicine and of Immunobiology and co-corresponding author of the study. The results are published today (September 1, 2021) in the journal Cell Metabolism. Dixit and his former colleague Emily Goldberg, now an assistant professor at UCSF, were curious about why fat tissue harbors immune system cells, which are usually concentrated in areas often exposed to pathogens like nasal passages, lungs, and skin. When they sequenced genes from cells of old and young mice they found that older animals lacked ILC2 cells, a deficit which limited their ability to burn fat and raise their body temperature in cold conditions. When scientists introduced a molecule that boosts the production of ILC2 in aging mice, the immune system cells were restored but the mice were surprisingly even less tolerant of cold temperatures. “The simple assumption is that if we restore something that is lost, then we are also going to restore life back to normal,” Dixit said. “But that is not what happened. Instead of expanding healthy cells of youth, the growth factor ended up multiplying the bad ILC2 cells that remained in fat of old mice.” But when researchers took ILC2 cells from younger mice and transplanted them into older mice, they found, the older animals’ ability to tolerate cold was restored. “Immune cells play a role beyond just pathogen defense and help maintain normal metabolic functions of life,” Dixit said. “With age, the immune system has already changed and we need to be careful how we manipulate it to restore the health of elderly.” Reference: “IL-33 causes thermogenic failure in aging by expanding dysfunctional adipose ILC2” by Emily L. Goldberg, Irina Shchukina, Yun-Hee Youm, Seungjin Ryu, Takeshi Tsusaka, Kyrlia C. Young, Christina D. Camell, Tamara Dlugos, Maxim N. Artyomov and Vishwa Deep Dixit, 1 September 2021, Cell Metabolism. DOI: 10.1016/j.cmet.2021.08.004

Researchers have identified a unique biomarker in the brain that signifies recovery from treatment-resistant depression, utilizing deep brain stimulation and artificial intelligence to understand and enhance treatment outcomes. A breakthrough study reveals a unique biomarker in the brain that tracks recovery from severe depression, using innovative deep brain stimulation and AI techniques. A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression published online in the journal Nature on September 20. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers from Emory University School of Medicine, Georgia Institute of Technology, and the Icahn School of Medicine at Mt. Sinai identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression. This pattern, known as a biomarker, serves as a measurable indicator of disease recovery and represents a significant advance in treatment for the most severe and untreatable forms of depression. The team’s findings offer the first window into the intricate workings and mechanistic effects of DBS on the brain during treatment for severe depression. How DBS Works and Its Impact DBS involves implanting thin electrodes in a specific brain area to deliver small electrical pulses, similar to a pacemaker. Although DBS has been approved and used for movement disorders such as Parkinson’s disease for many years, it remains experimental for depression. This study is a crucial step toward using objective data collected directly from the brain via the DBS device to inform clinicians about the patient’s response to treatment. This information can help guide adjustments to DBS therapy, tailoring it to each patient’s unique response and optimizing their treatment outcomes. Monitoring and Artificial Intelligence in Treatment Now, the researchers have shown it’s possible to monitor that antidepressant effect throughout the course of treatment, offering clinicians a tool somewhat analogous to a blood glucose test for diabetes or blood pressure monitoring for heart disease: a readout of the disease state at any given time. Importantly, it distinguishes between typical day-to-day mood fluctuations and the possibility of an impending relapse of the depressive episode. The research team used artificial intelligence (AI) to detect shifts in brain activity that coincided with patients’ recovery. The study, funded by the National Institutes of Health Brain Research Through Advancing Innovative Neurotechnologies, or the BRAIN Initiative, involved 10 patients with severe treatment-resistant depression, all of whom underwent the DBS procedure at Emory University. Advanced Techniques and Findings The study team used a new DBS device that allowed brain activity to be recorded. Analysis of these brain recordings over six months led to the identification of a common biomarker that changed as each patient recovered from their depression. After six months of DBS therapy, 90% of the subjects exhibited a significant improvement in their depression symptoms and 70% no longer met the criteria for depression. “This study demonstrates how new technology and a data-driven approach can refine DBS therapy for severe depression, which can be debilitating,” says John Ngai, PhD, director of the BRAIN Initiative. “It’s this type of collaborative work made possible by the BRAIN Initiative that moves promising therapies closer to clinical use.” The high response rates in this study cohort enabled the researchers to develop algorithms known as “explainable artificial intelligence” that allow humans to understand the decision-making process of AI systems. This technique helped the team identify and understand the unique brain patterns that differentiated a “depressed” brain from a “recovered” brain. Insights From Experts “The use of explainable AI allowed us to identify complex and usable patterns of brain activity that correspond to a depression recovery despite the complex differences in a patient’s recovery,” explains Sankar Alagapan PhD, a Georgia Tech research scientist and lead author of the study. “This approach enabled us to track the brain’s recovery in a way that was interpretable by the clinical team, making a major advance in the potential for these methods to pioneer new therapies in psychiatry.” Helen S. Mayberg, MD, co-senior author of the study, led the first experimental trial of subcallosal cingulate cortex (SCC) DBS for treatment-resistant depression patients at Emory University in 2003, demonstrating it could have clinical benefit. In 2019, she and the Emory team reported the technique had a sustained and robust antidepressant effect with ongoing treatment over many years for previously treatment-resistant patients. “This study adds an important new layer to our previous work, providing measurable changes underlying the predictable and sustained antidepressant response seen when patients with treatment-resistant depression are precisely implanted in the SCC region and receive chronic DBS therapy,” says Mayberg, now founding director of the Nash Family Center for Advanced Circuit Therapeutics at Icahn Mount Sinai. “Beyond giving us a neural signal that the treatment has been effective, it appears that this signal can also provide an early warning signal that the patient may require a DBS adjustment in advance of clinical symptoms. This is a game changer for how we might adjust DBS in the future.” “Understanding and treating disorders of the brain are some of our most pressing grand challenges, but the complexity of the problem means it’s beyond the scope of any one discipline to solve,” says Christopher Rozell, PhD, Julian T. Hightower Chair and Professor of Electrical and Computer Engineering at Georgia Tech and co-senior author of the paper. “This research demonstrates the immense power of interdisciplinary collaboration. By bringing together expertise in engineering, neuroscience and clinical care, we achieved a significant advance toward translating this much-needed therapy into practice, as well as an increased fundamental understanding that can help guide the development of future therapies.” Observations and Further Research The team’s research also confirmed a longstanding subjective observation by psychiatrists: as patients’ brains change and their depression eases, their facial expressions also change. The team’s AI tools identified patterns in individual facial expressions that corresponded with the transition from a state of illness to stable recovery. These patterns proved more reliable than current clinical rating scales. In addition, the team used two types of magnetic resonance imaging to identify both structural and functional abnormalities in the brain’s white matter and interconnected regions that form the network targeted by the treatment. They found these irregularities correlate with the time required for patients to recover, with more pronounced deficits in the targeted brain network correlated to a longer time for the treatment to show maximum effectiveness. These observed facial changes and structural deficits provide behavioral and anatomical evidence supporting the relevance of the electrical activity signature or biomarker. “When we treat patients with depression, we rely on their reports, a clinical interview, and psychiatric rating scales to monitor symptoms. Direct biological signals from our patients’ brains will provide a new level of precision and evidence to guide our treatment decisions,” says Patricio Riva-Posse, MD, associate professor and director of the Interventional Psychiatry Service in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, and lead psychiatrist for the study. Given these initial promising results, the team is now confirming their findings in another completed cohort of patients at Mount Sinai. They are using the next generation of the dual stimulation/sensing DBS system with the aim of translating these findings into the use of a commercially available version of this technology. For more on this research: Researchers Identify Crucial Biomarker That Tracks Recovery From Treatment-Resistant Depression Deep Brain Stimulation: A New Frontier in Tracking Depression Recovery Reference: “Cingulate dynamics track depression recovery with deep brain stimulation” by Sankaraleengam Alagapan, Ki Sueng Choi, Stephen Heisig, Patricio Riva-Posse, Andrea Crowell, Vineet Tiruvadi, Mosadoluwa Obatusin, Ashan Veerakumar, Allison C. Waters, Robert E. Gross, Sinead Quinn, Lydia Denison, Matthew O’Shaughnessy, Marissa Connor, Gregory Canal, Jungho Cha, Rachel Hershenberg, Tanya Nauvel, Faical Isbaine, Muhammad Furqan Afzal, Martijn Figee, Brian H. Kopell, Robert Butera, Helen S. Mayberg and Christopher J. Rozell, 20 September 2023, Nature. DOI: 10.1038/s41586-023-06541-3 Research reported in this press release was supported by the National Institutes of Health BRAIN Initiative under award number UH3NS103550; the National Science Foundation, grant No. CCF-1350954; the Hope for Depression Research Foundation; and the Julian T. Hightower Chair at Georgia Tech. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of any funding agency.

Scientists discovered how microbes build protein nanowires, enabling breakthroughs in energy, pollution control, and methane reduction. Credit: Yale University Yale researchers uncovered the molecular machinery behind nanowire assembly in microbes, enabling advances in electricity production, pollution mitigation, and methane reduction. Almost all living organisms breathe oxygen to remove excess electrons generated during the conversion of nutrients into energy. However, many microbes that play a crucial role in mitigating pollution and climate change lack access to oxygen. Instead, these bacteria—found buried underground or deep beneath oceans—have evolved a unique method of expelling electrons. They “breathe” minerals in the soil using tiny protein filaments known as nanowires. Unveiling the Machinery Behind Nanowires In previous research, a team led by Nikhil Malvankar, Associate Professor of Molecular Biophysics and Biochemistry at Yale’s Microbial Sciences Institute, showed that nanowires are made up of a chain of heme molecules, just like hemoglobin in our blood, thrust into the environment to move electrons. To leverage the power of these microbes, however, scientists need to know how those nanowires are assembled. The Yale team led by Cong Shen has now discovered the machinery that assembles the nanowires, making practical applications possible. Of the 111 heme proteins, only three are known to polymerize to become nanowires. Not only did the team identify the surrounding machinery that makes it possible for these proteins to become nanowires, but they also demonstrated that changing some of the machinery’s components can accelerate nanowire reproduction and bacterial growth. This is an important next step in engineering bacteria to efficiently produce electricity, clean pollutants from water, and lower atmospheric methane levels. Reference: “A widespread and ancient bacterial machinery assembles cytochrome OmcS nanowires essential for extracellular electron transfer” by Cong Shen, Aldo I. Salazar-Morales, Wonhyeuk Jung, Joey Erwin, Yangqi Gu, Anthony Coelho, Kallol Gupta, Sibel Ebru Yalcin, Fadel A. Samatey and Nikhil S. Malvankar, 15 January 2025, Cell Chemical Biology. DOI: 10.1016/j.chembiol.2024.12.013

DVDV1551RTWW78V